Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: Findings from the Jikei Heart Study

Journal of Hypertension

Volumn 28, Issue 6, 2010, Pages 1150-1157

  Yoshida, Hiroshi ^a,b   Shimizu, Mitsuyuki ^a,c   Ikewaki, Katsunori ^c,d   Taniguchi, Ikuo ^c   Tada, Norio ^b   Yoshimura, Michihiro ^c   Rosano, Giuseppe ^e   Dahlöf, Björn ^f   Mochizuki, Seibu ^c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b General Medicine Division   (United States)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin II receptor blocker; Cardiovascular outcomes; Hypertension; Sex; Valsartan

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; INSULIN; ISOSORBIDE DINITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICORANDIL; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; AORTA DISSECTING ANEURYSM; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; EVENT FREE SURVIVAL; FEMALE; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MORTALITY; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 77952468834     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328338a8b6     Document Type: Article

References (29)

1. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995; 18:181-196.
2. Ministry of Health, Labour, and Welfare, Japan. Statistical abstracts; 2004.
3. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34:2349-2354.
4. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update-endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113:2363-2372. (Pubitemid 43947981)
5. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results of the Third National Health and Nutrition Examination Survey. Hypertension 1995; 25:305-313.
6. Wassertheil-Smoller S,AndersonG, Psaty BM, Black HR, Manson J, Wong N, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 2000; 36:780-789.
7. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese Elderly. Arch Intern Med 2003; 163:361-366.
8. Kawano H, Soejima H, Kojima S, Kitagawa A, Ogawa H, Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Sex differences of risk factors for acute myocardial infarction in Japanese patients. Circ J 2006; 70:513-517.
9. Miyake Y. Risk factors for nonfatal acute myocardial infarction in middle-aged and older Japanese. Fukuoka Heart Study Group. Jpn Circ J 2000; 64:103-109.
10. Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, et al., MEGA Study Group. Usefulness of pravastatin in primary prevention of cardiovascular events in women. Circulation 2008; 117:494-502.
11. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosteron system blockade. J Hypertens 2005; 23 (Suppl 1):1-17.
12. Dzau V, Braunwald E. Resolved and resolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121:1244-1263.
13. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
14. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363:2022-2031.
15. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., LIFE study group. Cardiovascular mortality and morbidity in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
16. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, et al., Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369:1431-1439.
17. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24:2163-2168.
18. Mochizuki S, Shimizu M, Taniguchi I, Kanae K, Yoshida S, Tajima N, Dahlöf B, JIKEI HEART Study Group. JIKEI HEART study: a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease. Cardiovasc Drugs Ther 2004; 18:305-309.
19. Japanese Atherosclerotic Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases. Chapter 4: Risk factors of atherosclerotic diseases. J Atheroscler Thromb 2009; 16 (Suppl): 15-25.
20. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Committee report 10. Women. J Atheroscler Thromb 2008; 15:283-285.
21. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2006 update-a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113:85-151.
22. Sawada T, Yamada H, Dahlöf B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risk: Kyoto Heart Study. Eur Heart J 2009; 30:2461-2469.
23. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998; 7:176-183.
24. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051.
25. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43:2116-2123.
26. Saruta T. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Nippon Rinsho 2005; 63:952-958.
27. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitor and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
28. Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E, et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008; 51:1103-1108. (Pubitemid 351398965)
29. Trenkwalder P,Elmfeldt D, HofmanA,Lithell H,Olofsson B,Papademetriou V, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): major CV events and stroke in subgroups of patients. Blood Press 2005; 14:31-37.